[Form 4] Zivo Bioscience, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Christopher D. Maggiore, a director and reported >10% owner of Zivo Bioscience, Inc. (ZIVO), purchased 23,682 shares of the companys common stock on 10/08/2025 at a price of $12.01 per share. After this transaction the filing reports aggregate beneficial ownership of 517,526 shares, which corrects a prior overstatement caused by an administrative error that had overstated ownership by 13,156 shares. The transaction is reported on a Form 4 and was signed by the reporting person on 10/09/2025. The filing shows the acquisition coded as P and lists the ownership form as Direct.

Positive

• Insider acquisition of 23,682 shares at $12.01, indicating direct insider buying.
• Correction of prior overstatement by 13,156 shares improves accuracy of reported beneficial ownership.

Negative

• Administrative error overstated ownership by 13,156 shares, requiring correction.
• No additional detail on the source of funds or whether this follows a planned purchase program.

Insights

Corporate Governance Analyst

Insider purchase and a transparent correction of a reporting error.

The director and >10% owner increased direct holdings by 23,682 shares on 10/08/2025, bringing aggregate direct ownership to 517,526 shares after correcting an administrative overstatement of 13,156 shares. That correction improves accuracy of public insider records.

This type of purchase can be interpreted as alignment of a significant insider with shareholder outcomes; monitor subsequent filings for any additional buys or sales within the next several weeks to assess whether this is an isolated purchase or part of a pattern.

Equity Trading Analyst

Small open-market buy at a reported price of $12.01.

The transaction code P indicates a routine purchase; the per-share price reported is $12.01. The added position size is modest relative to the total aggregate reported holdings, raising direct ownership to 517,526 shares.

Given the corrected aggregate figure, short-term market impact is likely limited; traders may watch volume and subsequent Section 16 filings over the next 30 days for confirmation of trading trend or further insider activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maggiore Christopher D.

(Last) (First) (Middle)

2125 BUTTERFIELD ROAD

SUITE 100

(Street)

TROY MI 48084

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zivo Bioscience, Inc. [ ZIVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/08/2025		P		23,682	A	$12.01	517,526(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Due to an administrative error, the amount previously reported in this Item 5 overstated the aggregate beneficial ownership of the reporting person by 13,156 shares of Common Stock. The number stated in Item 5 to this Form 4 has been updated to correct the reporting person's aggregate beneficial ownership.

	/s/ Christopher D. Maggiore	10/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ZIVO director Christopher D. Maggiore buy on 10/08/2025?

He purchased 23,682 shares of ZIVO common stock on 10/08/2025 at $12.01 per share.

What is Christopher D. Maggiores total reported beneficial ownership after the transaction?

The filing reports aggregate beneficial ownership of 517,526 shares after correcting a prior overstatement.

Why was the aggregate ownership number changed?

An administrative error had overstated the aggregate beneficial ownership by 13,156 shares; the Form 4 updates Item 5 to correct that amount.

How is the transaction coded in the Form 4 and what does that mean?

The transaction is coded P, indicating a purchase; the filing lists the ownership form as Direct.

When was the Form 4 signed and filed?

The Form 4 is signed by Christopher D. Maggiore on 10/09/2025.